CompletedNCT04158453
AUT00201: Safety and Effects in Schizophrenia
About this title
Read the official source — NCT04158453Medication studyAges 18–65United Kingdom
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: October 10, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 80
- Sponsor
- Autifony Therapeutics Limited
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04158453
- Official title
Show the full official title
A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00201 in Healthy Male and Female Volunteers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Autifony Therapeutics Limited.
Did this study involve medication?
Yes. The study involved medication, including AUT00201 and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
